Surgery, octreotide, temozolomide, bevacizumab, radiotherapy and pegvisomant treatment of an AIP mutation positive child

Anil K Madugundu
Anil K Madugundu
Hitendra S Solanki
Hitendra S Solanki
Bishan D Radotra
Bishan D Radotra
Remya Raja
Remya Raja

The Journal of clinical endocrinology and metabolism, 2019.

Cited by: 0|Bibtex|Views7|Links
WOS

Abstract:

Multimodal treatment with surgery, octreotide-LAR, radiotherapy, temozolomide, bevacizumab and pegvisomant can control genetically driven aggressive childhood-onset somatotrophinomas.

Code:

Data:

Your rating :
0

 

Tags
Comments